Secondary Logo

Institutional members access full text with Ovid®

Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention

Wang, Xuechao; Li, Xinning; Wu, Haibo; Li, Ruyi; Liu, Huiliang; Wang, Lili; Bai, Shiru; Zhang, Lina; Chen, Tianlei; Liu, Jia; Li, Qi; Du, Rongpin

doi: 10.1097/MCA.0000000000000707
Original research: PDF Only
Buy
PAP

Background Ticagrelor significantly reduced the incidence of death, myocardial infarction, and stent thrombosis in patients with ST-segment elevation myocardial infarction (STEMI) intended for reperfusion with a primary percutaneous coronary intervention (pPCI). However, the effects of this drug on microvascular perfusion in patients presenting with STEMI have not been evaluated completely.

Patients and methods A total of 298 patients presenting with STEMI were randomized to either ticagrelor 180 mg loading, followed by 90 mg twice daily, or clopidogrel 600 mg loading, followed by 75 mg daily. The primary endpoint was ST-segment resolution at 90 min after pPCI. The secondary endpoints included myocardial blush grade and corrected thrombolysis in myocardial infarction frame count after the procedure. Left ventricular ejection fraction and major adverse cardiac events (MACE) at the 1- and 6-month follow-up time points were also recorded.

Results There were no significant differences between the two groups with respect to baseline characteristics. Ticagrelor administration resulted in a higher rate of completed ST-segment resolution (58.67 vs. 39.86%, P=0.001), higher myocardial blush grade (2.63±0.64 vs. 2.41±0.71, P=0.005), and lower corrected thrombolysis in myocardial infarction frame count (19.68±7.38 vs. 22.35±8.30, P=0.004). At 6 months, left ventricular ejection fraction was higher (55.01±8.44 vs. 52.34±9.05%, P=0.009) in the ticagrelor group. Kaplan–Meier analysis showed that MACE-free survival had also improved in the ticagrelor group during the 1- and 6-month follow-up time points.

Conclusion Compared with clopidogrel, ticagrelor improves myocardial perfusion and left ventricular ejection fraction, and reduces the incidence of MACE for STEMI patients undergoing pPCI, with no significant increase in major bleeding.

Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China

Correspondence to Rongpin Du, MD, Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei 050051, People’s Republic of China Tel/fax: +86 311 8598 8529; e-mail: doctorxinliu@163.com

Received September 18, 2018

Received in revised form December 14, 2018

Accepted December 22, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.